Overexpression of ezrin is associated with invasion and metastasis in head and neck squamous cell carcinoma (HNSCC) [23], pancreatic carcinomas [24], ovarian cancer [25], breast cancer [26], [27], ESCC [28], osteosarcoma [29] and lung carcinoma [30], [31]. Here, EZR is linked to esophageal squamous cell carcinoma.